Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-084363
Filing Date
2025-04-17
Accepted
2025-04-17 16:25:27
Documents
20
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A d929651ddef14a.htm   iXBRL DEF 14A 839554
3 GRAPHIC g929651dsp068.jpg GRAPHIC 214335
4 GRAPHIC g929651dsp069.jpg GRAPHIC 101053
5 GRAPHIC g929651g00r60.jpg GRAPHIC 104918
6 GRAPHIC g929651g00s03.jpg GRAPHIC 60280
7 GRAPHIC g929651g00s04.jpg GRAPHIC 54068
8 GRAPHIC g929651g00s05.jpg GRAPHIC 54547
9 GRAPHIC g929651g00s07.jpg GRAPHIC 152233
  Complete submission text file 0001193125-25-084363.txt   3217395

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aclx-20241231.xsd EX-101.SCH 2480
22 EXTRACTED XBRL INSTANCE DOCUMENT d929651ddef14a_htm.xml XML 158473
Mailing Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065
Business Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 240-327-0603
Arcellx, Inc. (Filer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41259 | Film No.: 25847655
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)